Finally, ubiquitin-like conjugation (UBL) gene mutations have recently been investigated as potential biomarkers for response stratification to second-line immunotherapy in NSCLC, demonstrating particularly strong predictive value among TP53 wild-type subgroups [75]. Here, TP53 is linked to non-small cell lung carcinoma.